NCT05341557View on ClinicalTrials.gov

A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

August 29, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions
Advanced Solid TumorLymphomaNSCLCHCC
Interventions
DRUG

BPI-371153

Subjects will receive BPI-371153 until disease progression

Trial Locations (4)

100021

RECRUITING

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Chaoyang

300060

RECRUITING

Tianjin Cancer Hospital, Tianjin

300070

RECRUITING

Tianjin Medical University General Hospital, Tianjin

062650

COMPLETED

Cangzhou Central Hospital, Cangzhou

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY

NCT05341557 - A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma | Biotech Hunter | Biotech Hunter